Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab (Helvetic BioPharma)
- Development stage
- Preclinical
- Lead developer
- Abbott
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Helvetic BioPharma's adalimumab is a biosimilar monoclonal antibody currently in preclinical development, specifically at the pilot scale production stage. It is designed to target and neutralize tumor necrosis factor-alpha (TNF-alpha), a potent pro-inflammatory cytokine that plays a central role in the pathogenesis of various systemic inflammatory diseases. By binding to TNF-alpha, the antibody prevents its interaction with the p55 and p75 cell surface TNF receptors, thereby downregulating the inflammatory cascade. This biosimilar is being developed for the treatment of autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and ankylosing spondylitis, mirroring the therapeutic profile of the reference product, Humira.
- Other names
- ADELIMUMABadalimumab biosimilar
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab (Helvetic BioPharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab (Helvetic BioPharma).